Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and 3-phenyllactic acid

fingolimod hydrochloride has been researched along with 3-phenyllactic acid in 1 studies

Compound Research Comparison

Studies
(fingolimod hydrochloride)		Trials
(fingolimod hydrochloride)		Recent Studies (post-2010)
(fingolimod hydrochloride)		Studies
(3-phenyllactic acid)		Trials
(3-phenyllactic acid)		Recent Studies (post-2010) (3-phenyllactic acid)
2,7711572,062134281

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Akbayir, E; Engevik, MA; Haag, AM; Haidacher, SJ; Hoch, KM; Horvath, TD; Kürtüncü, M; Oezguen, N; Palacio, J; Thapa, S; Türkoğlu, R; Tüzün, E; Versalovic, J; Yılmaz, V1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and 3-phenyllactic acid

ArticleYear
Serum 3-phenyllactic acid level is reduced in benign multiple sclerosis and is associated with effector B cell ratios.
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: B-Lymphocyte Subsets; Fingolimod Hydrochloride; Humans; Interleukin-4; Multiple Sclerosis

2022